Newsroom.

GC Biopharma, a global plasma manufacturing company distributing to over 50 countries, announced Mr. Woo Jin (WJ) Lee and Mr. John Menapace's appointment to GC Biopharma USA, Inc.'s executive leadership team. These appointments further contribute to GC's vision of establishing excellence within its US-based operations.

Mr. Lee joins GC Biopharma USA, Inc. as the new Chief Executive Officer (CEO), and Mr. Menapace joins as the Head of Finance and Operations for GC Biopharma USA, Inc.

Before joining GC Biopharma USA, Inc., Mr. Lee built his reputation growing GC Biopharma's global division, delivering pharmaceuticals to over 50 countries worldwide. He established alliances with international organizations such as the World Health Organization and the Pan American Health Organization. Mr. Lee is a well-respected leader holding various senior executive management positions throughout his career. With his appointment as the new CEO of US-based GC Biopharma USA, Inc., he continues his dedication to delivering top-quality pharmaceuticals and services and extending its vision of global healthcare.

Mr. John Menapace joins the GC Biopharma USA, Inc. executive team, bringing an extensive finance and plasma operations background. Before joining, Mr. Menapace was the Chief Financial Officer for the Floating Hospital, Javitis, and Kedrion Biopharma. His US plasma manufacturing and commercial start-up experience have been instrumental in building the operational framework of GC Biopharma USA, Inc.

"The additions of Mr. WJ Lee and Mr. John Menapace to the GC Biopharma USA, Inc. team strengthen our US operations and position us for growth and success with the pending launch of our IVIG 10% product," said President Huh. "We are confident the US business will capitalize on growth opportunities under their leadership."

About GC Biopharma USA, Inc.

GC Biopharma USA, Inc., Inc., headquartered in Fort Lee, NJ, established its sales, marketing, and business operations, in 2018 to serve customers and patients throughout the US. Our foundation is built on our parent company GC Biopharma's expertise, a leading biopharmaceutical company delivering plasma therapies and vaccines throughout the world. With GC Biopharma USA, Inc., GC Biopharma will further extend its footprint, bringing its expertise and legacy to the United States.

This press release may contain forward-looking statements that express GC Biopharma's and GC Biopharma USA, Inc.'s management's current beliefs and expectations. Such views do not represent any guarantee by either entity or its government of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma and GC Biopharma USA, Inc. undertake no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements they may make, except as required by law or stock exchange rule.